SCHEMBL1359893

SCHEMBL1359893

COc1cccc(-c2coc3c(C(C)(C)C)cc(-c4ccc[nH]c4=O)cc23)c1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ERCC5 P28715 1/20 0.43
FEN1 P39748 1/20 0.43
KCNA3 P22001 3/20 0.42
HPGD P15428 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
PPARG P37231 1/20 0.41
PPARD Q03181 1/20 0.41
PPARA Q07869 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CYP3A4 P08684 3/20 0.40
GSK3B P49841 1/20 0.39
PSMB8 P28062 1/20 0.36
GAA P10253 1/20 0.36
PKM P14618 1/20 0.36
BRD4 O60885 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1358251 0.86 CYP3A4 (0.38) ERCC5FEN1KCNA3HPGDALDH1A1
SCHEMBL1359548 0.86 BRAF (0.36) PPARGPPARDPPARACYP3A4
SCHEMBL1359206 0.83 BRD4 (0.39) CYP3A4GSK3BBRD4
SCHEMBL1360035 0.83 BRD4 (0.40) CYP3A4BRD4
SCHEMBL1360136 0.83 CYP3A4 (0.38) CYP3A4
SCHEMBL1358824 0.83 RAB9A (0.39) ERCC5FEN1ALDH1A1LMNAMAPT
SCHEMBL1359880 0.81 CYP3A4 (0.36) CYP3A4
SCHEMBL1359875 0.81 CYP3A4 (0.49) CYP3A4GSK3BBRD4
SCHEMBL1358345 0.81 CYP3A4 (0.41) MEN1KMT2ACYP3A4
SCHEMBL1359830 0.79 ALOX5AP (0.37) FEN1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067442-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2011-11-29 US claimed
EP-2334662-A1 PYRINE OR PYRAZINE DERIVATIVES FOR TREATING HCV F. Hoffmann-La Roche AG (CH) 2011-06-22 EP claimed
US-20100081658-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-04-01 US claimed
WO-2010034671-A1 PYRINE OR PYRAZINE DERIVATIVES FOR TREATING HCV F. HOFFMANN-LA ROCHE AG (CH) 2010-04-01 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081658-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS EIF2AK2, POLR2A, HCCS ERCC5 1834/4885FEN1 2601/4885KCNA3 4211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.